1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deacon, J; Holliday, S; Stratford, IJ; Walling, JM | 1 |
| Ahmed, I; Deacon, JM; Holliday, SB; Jenkins, TC | 1 |
2 other study(ies) available for 1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol and Malignant Melanoma
| Article | Year |
|---|---|
High uptake of RSU 1069 and its analogues melanotic melanomas.
Topics: Animals; Cell Line; Cell Membrane Permeability; Deoxyribonucleases; Drug Evaluation, Preclinical; Half-Life; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Microbial Collagenase; Misonidazole; Sarcoma, Experimental; Tissue Distribution; Trypsin; Tumor Cells, Cultured | 1989 |
Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios.
Topics: Animals; Male; Melanoma; Mice; Mice, Inbred C57BL; Misonidazole; Neoplasm Transplantation; Radiation-Sensitizing Agents | 1986 |